293780.KQ
AptaBio Therapeutics Inc.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,620.00
+4.91%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.8B | 3.7B | 3.4B | 323.9M | 48.4M |
| Cost of Revenue | 2.7B | 2.8B | 3.1B | 262.8M | 11.1M |
| Gross Profit | 2.1B | 874.5M | 286.6M | 61.1M | 37.2M |
| Operating Expenses | |||||
| R&D Expense | 13.8B | 10.5B | 14.6B | 12.4B | 6.2B |
| SG&A Expense | 7.2B | 2.9B | 1.6B | 1.5B | 2.8B |
| General & Admin Expense | 4.3B | 625.4M | 445.9M | 477.3M | 476.7M |
| Selling & Marketing Expense | 1.2B | 2.3B | 1.2B | 1.0B | 678.7M |
| Other Expenses | 5.9B | 3.0B | 2.9B | 2.6B | 2.2B |
| Total Operating Expenses | 20.8B | 16.4B | 19.1B | 16.5B | 9.0B |
| Cost and Expenses | 23.5B | 19.2B | 22.2B | 16.7B | 9.5B |
| Operating Income (EBIT) | (18.4B) | (15.5B) | (18.9B) | (16.4B) | (9.5B) |
| Non-Operating | |||||
| Interest Income | 691.0M | 981.5M | 2.0B | 2.0B | 1.6B |
| Interest Expense | 1.7B | 2.1B | 3.4B | 1.2B | 4.5M |
| Net Interest Income | (1.0B) | (1.1B) | (1.4B) | 801.3M | 1.6B |
| Other Non-Op Income/Expense | 4.5B | 162.7M | (8.9B) | 1.7B | (1.1B) |
| Non-Operating Income (excl Interest) | (814.1M) | — | 5.5B | (2.9B) | 1.1B |
| EBT (Pre-Tax Income) | (13.9B) | (15.3B) | (27.8B) | (14.7B) | (10.6B) |
| Income Tax Expense | 1.0B | 1.0B | 1.6B | (2.6B) | 460.2M |
| Bottom Line | |||||
| Net Income | (14.9B) | (16.3B) | (29.4B) | (12.1B) | (10.6B) |
| Earnings from Cont. Ops | (14.9B) | (16.3B) | (29.4B) | (12.1B) | (10.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.9B) | (16.3B) | (29.4B) | (12.1B) | (10.6B) |
| Per Share | |||||
| Basic EPS | (₩554) | (₩607) | (₩1,274) | (₩532) | (₩474) |
| Diluted EPS | (₩554) | (₩607) | (₩1,274) | (₩532) | (₩474) |
| Revenue Per Share | ₩169 | ₩137 | ₩146 | ₩14 | ₩2 |
| Shares | |||||
| Basic Shares Outstanding | 28.1M | 26.9M | 23.1M | 22.7M | 22.3M |
| Diluted Shares Outstanding | 28.1M | 26.9M | 23.1M | 22.7M | 22.3M |
| Profitability Metrics | |||||
| EBITDA | (22.9B) | (15.0B) | (23.9B) | (13.0B) | (10.1B) |
| D&A | 399.9M | 455.7M | 531.4M | 539.1M | 460.4M |
| EBIT | (23.3B) | (15.5B) | (24.4B) | (13.5B) | (10.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026